Literature DB >> 947930

Changes in serum triiodothyronine, thyroxine, and thyrotropin during treatment with thyroxine in severe primary hypothyroidism.

M Maeda, N Kuzuya, Y Masuyama, Y Imai, H Ikeda.   

Abstract

Studies were performed on 40 patients with severe primary hypothyroidism, during treatment with varying doses of T4. Therapy was initiated with 50 mug/day and was continued for at least 2 months. Subsequent repeated increases of 25 mug/day were continued for at least 2 months until the serum TSH level was less than 10 muU/ml. Measurements of serum T4 and T3, RT3U, and serum TSH were carried out at monthly intervals. TRH tests were performed after TSH levels of less than 10 muU/ml had been attained and the dose of T4 had been maintained for at least 2 months. In most of the samples obtained during treatment with various doses of T4 (50-175 mug/day), serum T4 concentrations were within the normal range, even when patients were receiving only 50 mug/day of T4; however, approximately 60% of the samples had subnormal T3 concentrations. Fifty per cent of the samples had elevated TSH concentrations despite normal T4 levels, while only 7% of the samples with normal T3, as well as T4, levels had slightly elevated TSH concentrations. Similar relationships were observed between serum TSH and free T4 indices and free T3 indices. Among patients with serum TSH levels of less than 10 muU/ml, none showed subnormal T4 concentrations, while subnormal T3 concentrations were found in some of them. Hyper-response to TRH was noted in patients with subnormal T3 levels, and normal responses were observed in patients with normal T3 and T4 concentrations. These data indicate that, during the treatment of hypothyroidism with T4, 1) normal basal TSH correlates better with normal serum T4 and T3 than with normal T4 alone, 2) the response of TSH to TRH is supranormal in patients with subnormal T3 levels, in spite of normal basal TSH and T4, and 3) the calculated maintenance dose of T4, which is associated with a normal TRH response, is 2.08 mug/day/kg of body weight.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947930     DOI: 10.1210/jcem-43-1-10

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Goiter: an approach to management.

Authors:  W C Nicholas
Journal:  Can Fam Physician       Date:  1978-04       Impact factor: 3.275

Review 2.  The emergence of levothyroxine as a treatment for hypothyroidism.

Authors:  James V Hennessey
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

3.  An approach to investigation of the changing pattern of plasma cyclic nucleotides and their correlation with thyroid hormone in hyperthyroid patients before and after 131I treatment.

Authors:  Y G Zhang; W X Ye
Journal:  Acta Acad Med Wuhan       Date:  1983

4.  Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: a case for "tissue thyrotoxicosis".

Authors:  P E Jennings; B P O'Malley; K E Griffin; B Northover; F D Rosenthal
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

5.  Maintenance requirements of L-thyroxine in the treatment of hypothyroidism.

Authors:  W A Kehoe; B J Dong; F S Greenspan
Journal:  West J Med       Date:  1984-06

6.  Elevated serum thyroxine concentration in patients receiving "replacement" doses of levothyroxine.

Authors:  J C Ingbar; M Borges; S Iflah; R E Kleinmann; L E Braverman; S H Ingbar
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

Review 7.  Clinical use of sensitive assays for thyroid-stimulating hormone.

Authors:  P A Masters; R J Simons
Journal:  J Gen Intern Med       Date:  1996-02       Impact factor: 5.128

8.  Management of patients with congenital hypothyroidism.

Authors:  G J Frost; J M Parkin
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

9.  Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment.

Authors:  B Busnardo; M E Girelli; F Bui; G P Zanatta; M Cimitan
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.